To the best of our knowledge, this study represents the largest and most comprehensive analysis of post-marketing AEs involving BRAF/MEKi for melanoma treatment, with a specific focus on CV toxicity, using data from a worldwide SRS database. This evidence concerns the gene BRAF and melanoma.